Key points
- Neuren's earned royalty income from DAYBUE® increased by 29% in US dollars
- Research and development costs increased by A$12.5 million
- Net profit after tax for H1 2026 was A$4.9 million, down from A$15.0 million in H1 2025
- Neuren introduced its first dividend policy and declared a fully franked interim dividend
Full summary
Neuren Pharmaceuticals Ltd reported its half-yearly financial results for the period ended 30 June 2026. The company's revenue from ordinary activities increased by 8% to A$42.7 million, driven by a 29% rise in earned royalty income from Acadia Pharmaceuticals for DAYBUE® (trofinetide). Research and development costs rose by A$12.5 million to A$27.4 million, primarily due to the progression of the NNZ-2591 Phase 3 clinical trial in Phelan-McDermid syndrome. Despite these increases, the company's profit after income tax fell to A$4.9 million from A$15.0 million in the same period last year. The company introduced its first dividend policy and declared a fully franked interim dividend of 15.0 cents per share.
Guidance
Neuren Pharmaceuticals Ltd expects royalties for full year 2026 to be between US$53-56 million.
Outlook
Neuren Pharmaceuticals Ltd anticipates continued growth in DAYBUE® sales and expects to meet with the FDA in H1 2027 to discuss the clinical development program for NNZ-2591.